Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Avonex®: Safety, Blood Levels and Effects (C-851)

This study has been completed.
Biogen Idec
Information provided by (Responsible Party):
Trio Medicines Ltd. Identifier:
First received: May 20, 2013
Last updated: May 22, 2013
Last verified: May 2013

The primary objective was to determine the tolerability of a new inhaled formulation of interferon beta-1a when given as a single dose, when given once per week for 4 weeks, and compared with standard intramuscular (IM) AVONEX® when given as a single dose.

The additional objectives were:

To determine the pharmacokinetic (PK) properties of a new inhaled formulation of interferon beta-1a, using an anti-viral cytopathic effect (CPE) assay for human interferon-beta, when given as a single dose, when given once per week for 4 weeks, and compared with standard IM AVONEX® when given as a single dose.

To determine the pharmacodynamic (PD) properties of a new inhaled formulation of interferon beta-1a, as measured by serum neopterin and 2-microglobulin, when given as a single dose, when given once per week for 4 weeks, and compared with standard IM AVONEX® when given as a single dose.

Condition Intervention Phase
Multiple Sclerosis (MS)
Drug: Interferon beta 1a
Drug: (IM) AVONEX®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Trio Medicines Ltd.:

Primary Outcome Measures:
  • Pharmacokinetic parameter [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Serum concentrations of human interferon-beta

  • Pharmacodynamic parameter [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Serum concentrations of neopterin and beta2-microglobulin

  • Number of adverse events [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Adverse events throughout the study

  • Clinically relevant changes from baseline in safety assessments [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Routine physical examination, ECG, safety tests of blood/urine, CXR, oximetry, full pulmonary function tests, spirometry, Dyspnea scale

  • Pharmacodynamic paramter [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Cellular MxA protein as an exploratory analysis

Enrollment: 77
Study Start Date: January 2001
Study Completion Date: October 2001
Primary Completion Date: October 2001 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Interferon beta 1a
    Other Name: AVONEX
    Drug: (IM) AVONEX®

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Must be between the ages of 18 and 45 years, inclusive.
  • Must have a body mass index (BMI) of 19 to 28 kilograms/height (m)2, inclusive, and have a minimum body weight of 50 kilograms (at screening and baseline).
  • Must give written informed consent.

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions.
  • History of hypersensitivity to acetaminophen (paracetamol) or ibuprofen. Subjects in Part III of the study will also be excluded for history of hypersensitivity to human albumin.
  • History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease.
  • History of asthma, as defined by wheezing, dyspnea, or cough requiring treatment with either inhaled beta-2-agonists, inhaled corticosteroids, inhaled cromolyn sodium, or oral steroids or history of chronic obstructive pulmonary disease (including chronic bronchitis, bronchiectasis, or emphysema).
  • Abnormal screening full pulmonary function tests (PFTs) or baseline spirometry (predicted values are those of the European Coal and Steel Community (Quanjer, 1983)) or abnormal screening or baseline oximetry, as defined by any one of the following:

    • <80% predicted Forced expiratory volume (FEV1)
    • <80% predicted forced vital capacity (FVC)
    • <70% FEV1/FVC ratio
    • <80% predicted total lung capacity (TLC)
    • <80% predicted diffusion capacity, corrected for hemoglobin (DLCOcorr).
    • Oxygen saturation of <96% on room air at rest.
  • Inability to perform pulmonary function tests in a reproducible manner.
  • Inability to use the Pulmonary Delivery System device correctly.
  • Abnormal baseline or screening dyspnea scale, defined as a score of equal to or greater than 1 on the modified Medical Research Council (MRC) scale.
  • Fever (body temperature >38 degrees C) or symptomatic viral or bacterial infection (including upper respiratory infection) within 1 week prior to the first day of dosing.
  • Abnormal baseline or screening blood tests exceeding any of the limits defined below:

    • Alanine transaminase (ALT) or aspartate transaminase (AST) or bilirubin > 2x the upper limit of normal (> 2x ULN)
    • Total white blood cell count (WBC) < 3700/mm3
    • Platelet count < 150,000/mm³
    • Hemoglobin < 12 g/dL
    • Plasma Creatinine > ULN
    • Prothrombin time (PT) or activated thromboplastin time (aPTT) > ULN
    • Positive for hepatitis C antibody, hepatitis B surface antigen (HBsAg), or HIV antibody.
  • An electrocardiogram (ECG) with a clinically significant abnormality (as determined by the investigator).
  • A chest radiograph (CXR) with a clinically significant abnormality (as determined by the investigator).
  • History of epilepsy or fits or unexplained blackouts.

Treatment History

  • Previous treatment with any interferon beta or any interferon alpha product.
  • Treatment with another investigational drug or approved therapy for investigational use within 3 months prior to the first day of dosing.
  • Except for contraceptives, vitamin/mineral supplements, acetaminophen (paracetamol), and/or ibuprofen, treatment with any medication including over-the-counter products within 48 hours prior to the first dose of study drug.


  • History of smoking within 6 months prior to the first day of dosing.
  • Abnormal screening urine cotinine level (defined as >100 ng/mL when performed by capillary column gas-liquid chromatography).
  • History of drug or alcohol abuse (as defined by the investigator) within the 2 years prior to the first day of dosing.
  • Blood donation (one unit or more) within 1 month prior to the first day of dosing.
  • Vigorous exercise (as determined by the investigator) within 48 hours prior to the first dose of study drug.
  • Alcohol use within 24 hours prior to the first dose of study drug.
  • Female subjects who are currently pregnant or breast-feeding.
  • For female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the investigator, during the study. The rhythm method is not to be used as the sole method of contraception. Women considering becoming pregnant while on study are to be excluded.
  • Positive screening or baseline urine drug screen
  • Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's returning for follow-up visits on schedule.
  • Current enrollment in any other study.
  • Previous participation in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01863069

United Kingdom
Hammersmith Medicines Research
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Trio Medicines Ltd.
Biogen Idec
Principal Investigator: Steve Warrington Hammersmith Medicines Research
  More Information

No publications provided

Responsible Party: Trio Medicines Ltd. Identifier: NCT01863069     History of Changes
Other Study ID Numbers: 00-037
Study First Received: May 20, 2013
Last Updated: May 22, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Trio Medicines Ltd.:
interferon beta-1a
healthy subjects

Additional relevant MeSH terms:
Multiple Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Interferon beta 1a
Adjuvants, Immunologic
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 27, 2015